Cyberonics reneged on its "Lifetime Reimbursement Guarantee". Click on the image to learn how you can help...
Showing posts with label stroke. Show all posts
Showing posts with label stroke. Show all posts

Monday, July 13, 2015

TIRR Memorial Hermann is one of three U.S. sites participating in stroke trial

July 13, 2015

TIRR Memorial Hermann is one of three U.S. sites participating in stroke trial

Posted: Wednesday, July 8, 2015 4:25 pm

TIRR Memorial Hermann is one of three U.S. sites participating in stroke trial

TIRR Memorial Hermann is taking part in a clinical trial aimed at assessing Vagus Nerve Stimulation (VNS) during rehabilitation for improved upper limb motor function following a stroke. According to the American Heart Association, someone in the United States has a stroke every 40 seconds and stroke is a leading cause of disability in the United States.

The goal of this research is to improve and maximize arm and hand function in stroke survivors. The current study is an extension of a clinical trial conducted last year in Europe. Following the European clinical trial, some patients were able to resume daily activities like driving, cooking, and taking care of young children.

TIRR Memorial Hermann is one of only three sites in the United States participating in this trial. Dr. Gerard E. Francisco, chief medical officer at TIRR Memorial Hermann and Professor and Chairman of Physical Medicine and Rehabilitation Department (PM&R) at UT-Health and Dr. Nuray Yozabitran, researcher in the UTHealth Neuromodulation and Neural Interfaces Laboratory at TIRR Memorial Hermann’s NeuroRecovery Research Center are coordinating the Houston trial.

“At TIRR Memorial Hermann we’re known around the world for our rehabilitation services. But the cutting edge research we are doing is important so that we can continue to rehabilitate even better,” says Dr. Francisco. “The results from the European clinical trial were very promising and we’re excited to get our research underway.”

The trial requires an outpatient surgical procedure to place an electrical device in the patient’s chest area. The device is then connected to the vagus nerve in the neck using thin wires that are also implanted.

The vagus nerve directly connects to the brain and sends important signals to tell the brain what to learn. The patient will do a series of therapeutic tasks aimed at rebuilding the neural circuits in the brain that are responsible for upper limb movement. Each time the patient completes a correct movement, the therapist pushes a button and the patient receives a small burst of neurostimulation, which activate the vagus nerve. VNS aims to encourage the growth of new neural connections in the brain that may have been damaged by a stroke.

The treatment uses the Vivistim System developed by Texas based medical device firm MicroTransponder.

To participate in the trial you must be between the ages of 30 and 80 and have had a stroke at least four months ago but not more than five years ago. You must also experience some arm and hand movement difficulties.

To learn more about the trial go to http://www.vnsstroketrial.com/ or call (713) 797-5282.

http://www.fbherald.com/tirr-memorial-hermann-is-one-of-three-u-s-sites/article_77c42680-5f77-5943-9ef5-7480a81b1ada.html

Saturday, May 9, 2015

UT Southwestern Among Sites to Test Implant Device’s Ability to Restore Arm Function Post-Stroke

UT Southwestern Among Sites to Test Implant Device’s Ability to Restore Arm Function Post-Stroke

Published on May 8, 2015

ut

A recent university news release from UT Southwestern Medical Center reports that the center will be one of three national sites to pioneer US testing for an implant device designed to stimulate the vagus nerve in stroke patients; the aim is to determine whether the technology can help restore lost arm function.

The release states that the device, known as the Vivistim System, was developed by Dallas-based company MicroTransponder Inc with a license from UT Dallas. The technology is engineered to stimulate the neck’s vagus nerve. It is implanted under the collarbone and is about the size of a pacemaker. According to the release, it sends painless, half-second electrical pulses up the vagus nerve, causing neruomodulators to be released in various parts of the brain. There are also alternate forms of vagus nerve stimulation therapy already approved for use by the FDA for treating other illnesses, such as depression and epilepsy, the release adds.

The neuromodulators “appear to facilitate the creation of new neuron pathways in the brain, which play a key role in restoring muscle movement,” says Ty Shang, MD, PhD, in the release.

Shang is an assistant professor of Neurology and Neurotherapeutics, UT Southwestern, and is heading the UT Southwestern arm of the trial.

A stroke deprives brain cells of oxygen, and without oxygen, brain cells die and can no longer perform the function for which they were intended, Shang points out.

“There has been no known way to regenerate new brain cells to replace them, but in early tests with this device, the brain appears to ‘rewire’ other cells to perform the function,” he adds.

The Vivistim System is built to improve motor function in the more involved arm of a patient post-stroke. The technology was studied beginning in 2013 for efficacy and safety in a small study in Glasgow, Scotland, the release says. Individuals in the Glasgow study reportedly experienced meaningful, functional improvements in their more involved arm.

Shang theorizes that VNS therapy may serve as the stimulus for motor relearning with the more involved arm for individuals post-stroke. While gaining functional improvement in the impaired arm can be a challenge, Shang says, “VNS therapy might make achieving functional gains easier.”

The release notes that currently, UT Southwestern researchers are seeking individuals in the Dallas-Fort Worth metroplex who sustained a stroke 4 months to 5 years ago to participate in the trial.

Once participants have undergone outpatient surgery to implant the device, the release says they will be scheduled for 18, 90-minute sessions of intensive, task-specific therapy during a 6-week period, with quarterly follow-up evaluations for the next year.

Interested participants can visit www.vnsstroketrial.com or contact the Department of Physical Therapy at (214) 648-1533.

[Photo Credit: UT Southwestern Medical Center]

[Source(s): Newswise, UT Southwestern Medical Center]

http://www.ptproductsonline.com/2015/05/ut-southwestern-one-sites-test-implant-device-designed-restore-arm-function-post-stroke/#sthash.flR5WI14.dpuf

Tuesday, March 10, 2015

Treatment for stroke victims shows ‘promising’ results

 

        • Wednesday 11th March 2015

Treatment for stroke victims shows ‘promising’ results

Them trial recruited 20 patients in Glasgow and Newcastle. Picture: John Devlin

Them trial recruited 20 patients in Glasgow and Newcastle. Picture: John Devlin

 

TIM BUGLER

22:58 Tuesday 10 March 2015 00:00 Wednesday 11 March 2015

A GROUND-BREAKING new treatment to help stroke patients regain the use of their arms has shown “promising” ­results.

Vagus nerve stimulation (VNS) uses small doses of electricity to encourage the growth of new neural connections in the brain.

It has now been shown to help patients improve arm function by a greater degree than standard physiotherapy alone.

A stroke happens as a result of a loss of blood supply to a part of the brain, leading to tissue death and loss of functions controlled by the affected brain area. Around 85 per cent of stroke victims seen at the stroke clinic at Glasgow’s Western Infirmary have arm weakness, which persists to a significant degree in half of these.

The two-year trial, which recruited 20 patients in Glasgow and Newcastle-upon-Tyne with long-term arm weakness after their stroke, involved the implantation of a small electrical device into the body.

The device is similar to a pacemaker and is implanted in the chest. It is then connected to the vagus nerve in the neck using thin wires that are also implanted. Scientists decided to stimulate the vagus nerve as it connects to structures in the brain involved in recovery from injury. The idea was to take ­advantage of neuroplasticity – the natural ability of the brain to form new neural connections.

Pairing the vagus nerve stimulation with traditional rehabilitation encourages the brain to form new, stronger neural connections. The researchers in this study hoped this process would significantly improve arm function during the recovery process following the stroke.

The study recruited volunteers who had suffered ischaemic stroke at least six months earlier with moderately severe arm problems. The patients were split into two groups, one receiving intensive physiotherapy alone, the other receiving physiotherapy paired with VNS.

When patients followed the study protocol in full, there was a significantly greater improvement in a measure of arm function called the upper extremity Fugl-Meyer score.

The scores of VNS treated patients were six points higher than those who did not receive VNS in addition to their physiotherapy. When patients have such a large change in their score, noticeable improvements in arm related tasks can be ­observed on a daily basis.

Dr Jesse Dawson, of the Institute of Cardiovascular and Medical Sciences at Glasgow University, who led the trial, said: “Our initial study demonstrates that VNS paired therapy holds promise. Greater improvements in arm function were observed in patients using VNS paired therapy compared to participants using traditional rehabilitation alone.

“We need to do larger trials to confirm our findings and determine if the widespread adoption of this technique could benefit post-stroke patients with upper limb deficits. These initial results are certainly encouraging and warrant further investigation.”

The trial was run with Texas-based biomedical company MicroTransponder, which developed the “Vivistim” device.

http://www.scotsman.com/news/health/treatment-for-stroke-victims-shows-promising-results-1-3715354

Saturday, October 18, 2014

Grant Enables Researchers to Continue Studying Stroke Recovery

research

Grant Enables Researchers to Continue Studying Stroke Recovery

Oct. 20, 2014

Dr. Michael Kilgard

Dr. Michael Kilgard

Dr. Robert Rennaker

Dr. Robert Rennaker

At UT Dallas, researchers are developing new techniques to aid recovery from stroke. Their efforts recently received a boost thanks to a multimillion-dollar grant from the National Institutes of Health.

Drs. Michael Kilgard and Robert Rennaker will receive $2.3 million over the next five years to test the effectiveness of using vagus nerve stimulation (VNS) to enhance recovery from stroke in an older population.

According to the Centers for Disease Control and Prevention, more than 795,000 people in the United States will experience a stroke every year. Survivors are often left with weakness or paralysis of their limbs.

“Things like feeding yourself, brushing your teeth, putting your clothes on by yourself — all of those things are almost impossible if you’ve lost upper limb function on one side,” said Rennaker, head of the bioengineering department and director of the Texas Biomedical Device Center at UT Dallas.

Stroke is the No. 1 cause of disability in the United States, but it is also one of the easiest neurological disorders to study because it has a clearly defined cause, according to Kilgard, the Margaret Fonde Jonsson Professor in the School of Behavioral and Brain Sciences. Other brain disorders are more difficult to study because they result from multiple breaks in the nervous system, or their origins are not fully understood, he said.

Strokes occur when blood flow to the brain is interrupted, due to either a blockage (ischemic stroke) or a ruptured blood vessel (hemorrhagic stroke). Blood normally delivers life-sustaining oxygen to the brain. But without that timely and constant delivery, the affected areas become damaged and can eventually result in disability or death to the individual.

Some recovery can occur naturally after a stroke and restore some of the lost brain function. The ability of the brain to change after a stroke is referred to as neuroplasticity. Kilgard and Rennaker are using VNS to try to enhance that neuroplasticity and increase the recovered motor function.

VNS is an FDA-approved method for treating various illnesses, such as depression and epilepsy. It involves sending a mild electric pulse through the vagus nerve, which is in the neck and relays information about the state of the body to the brain.

“We’re interested in learning what is changing in the brain as a result of the VNS therapy, and how those changes lead to recovery.”

Dr. Michael Kilgard,
the Margaret Fonde Jonsson Professor in the School of Behavioral and Brain Sciences

Recent research at UT Dallas explored the use of VNS to enhance recovery from the two types of stroke. Last year, Dr. Navid Khodaparast published research describing the complete recovery of animals’ upper limb function after an ischemic stroke. In August, Dr. Seth Hays demonstrated an improvement in recovery from a hemorrhagic stroke in rats.

The new research project will employ an animal model to examine how effective VNS therapy is in an older population. According to the American Heart Association, the risk of having a stroke approximately doubles for every decade of life over 55 years.

“We’re interested in learning what is changing in the brain as a result of the VNS therapy, and how those changes lead to recovery,” Kilgard said.

Specifically, the researchers will examine changes in dendrites, the part of nerve cells in the brain that receives signals from other neurons. They’ll focus on the motor cortex region of the brain controlling upper limb function. They predict VNS therapy might increase dendritic growth in areas of the brain involved in recovery.

Researchers also will examine the connections between the neurons across the two sides of the brain. In a healthy animal, the right side of the brain controls the left side of the body and vice versa for the other side. In an animal recovering from brain damage to one side, recovery could be due to the surrounding undamaged areas taking over the work of the damaged areas or the other side of the brain taking over. Tracing the connections will allow the researchers to see which area of the brain is taking control, providing insight into where the recovery is taking place.

“Although we focus a lot on figuring out the basic science behind why VNS therapy works, our overall goal is to eventually improve the lives of patients,” Kilgard said. “Research like this will help us do that.”

Media Contact: Ben Porter, UT Dallas, (972) 883-2193, ben.porter@utdallas.edu
or the Office of Media Relations, UT Dallas, (972) 883-2155, newscenter@utdallas.edu.

http://www.utdallas.edu/news/2014/10/20-31243_Grant-Enables-Researchers-to-Continue-Studying-Str_story-wide.html?WT.mc_id=NewsHomePage

Wednesday, June 11, 2014

Nexstim Initiates Multicenter Clinical Trial on the Therapeutic Effects of Navigated TMS for Stroke Rehabilitation

Nexstim Initiates Multicenter Clinical Trial on the Therapeutic Effects of Navigated TMS for Stroke Rehabilitation

June 11, 2014

ALPHARETTA, Ga. — Nexstim has launched a multicenter double-blinded, randomized, and sham-controlled trial to determine the therapeutic effects of navigated rTMS (repetitive transcranial magnetic stimulation) for stroke rehabilitation. This cutting-edge stroke therapy combines occupational therapy with nTMS (navigated transcranial magnetic stimulation). Called the NICHE trial (Navigated Inhibitory rTMS in Contralesional Hemisphere Evaluation), this two year study will be conducted at twelve of the top rehabilitation sites in the United States.

“The trial results are showing great potential for non-invasive brain modulation and the difference Nexstim is providing is the proven Navigation to enable this approach.” - Janne Huhtala, CEO, Nexstim

Dr. Richard Harvey, Medical Director, Center for Stroke Rehabilitation, Rehabilitation Institute of Chicago (RIC), developed the protocol with Nexstim and ran the single center trial. Dr. Harvey and his team at RIC presented the trial results at the American Heart Association’s International Stroke Conference in February, ‘The Contrastim Stroke Study: Improving Hand and Arm Function After Stroke with Combined Non-Invasive Brain Stimulation and Task-Oriented Therapy’ (presentation #152).

Dr. Harvey’s study approached stroke rehabilitation through a new combination of therapies which produced significantly greater gains in patients’ motor function 6 months post stroke. The combination of non-invasive navigated transcranial magnetic stimulation (nTMS) along with occupational therapy opened the door to improving the quality of life for stroke survivors. The study showed over 80% of the active group received a clinically meaningful response rate.

Researchers working at the following trial sites, will enroll up to 200 patients, and will look to replicate the initial findings.

Arizona

Mayo Clinic

California

Ranchos Los Amigos National Rehabilitation Institute

Georgia

Shepherd Center

Illinois

Rehabilitation Institute of Chicago

Indiana

Indiana University

Massachusetts

Spaulding Rehabilitation Hospital

New York

Columbia University

Burke Rehabilitation Center

North Carolina

Duke University

Ohio

Ohio State University

University of Cincinnati

Texas

TIRR Memorial Hermann Hospital

About the Technology:

The NBS System uses stereotactic MRI-guided transcranial magnetic stimulation (TMS) to non-invasively modulate precise areas of the motor cortex. The system’s e-field based targeting tool allows the therapist to accurately locate the patients exact stimulation target using technology similar to mapping the globe with a GPS. The nTMS is used to stimulate the patient’s non-injured brain hemisphere at a low frequency. This results in down-regulation of the excitability of the healthy side and restoration of the balance between the lesioned and healthy sides, allowing the lesioned side to regain function. Adding navigation to TMS is the key to finding the exact location and orientation of the e-field of the motor area that should be inhibited by stimulation. The stimulation is then accurately repeated in every session, assuring the dose is applied to the correct place.

About Nexstim:

Founded in 2000, Nexstim is committed to improving the quality of life of patients with significant unmet clinical needs. The advanced technology providing navigation to TMS has led to Nexstim being the world leader in image-guided transcranial magnetic stimulation (TMS). Nexstim has pioneered the technology for brain diagnostics and with FDA-clearance of the Navigated Brain Stimulation (NBS) System for non-invasive pre-surgical mapping. NBS is recognized as the emerging standard for pre-operative direct functional mapping. Nexstim’s NBS System enables treatment of brain injury and disease using rTMS with accurate and repeatable 3D-guidance of therapeutic electrical field.

Nexstim’s non-invasive Navigated Brain Stimulation System is not approved by the Food and Drug Administration for therapy in commercial use in the United States and is available to select physician for investigational use only.

http://www.heraldonline.com/2014/06/11/6048156/nexstim-initiates-multicenter.html?sp=/100/773/385/#storylink=cpy

Monday, July 29, 2013

Magnetic Brain Stimulation Shown To Increase Speech Skills Of Stroke Victims

Magnetic Brain Stimulation Shown To Increase Speech Skills Of Stroke Victims

July 29, 2013

Image Credit: Lightspring / Shutterstock

redOrbit Staff & Wire Reports – Your Universe Online

Stroke patients who have parts of their brain stimulated with a magnetic coil prior to taking part in speech and language therapy made three times as much progress than those who did not undergo the procedure, according to research recently published in the journal Stroke.

By using a non-invasive technique to temporarily shut down the parts of the brain that function properly, researchers from McGill University in Montreal discovered the side of the brain that had been damaged by the stroke could re-learn linguistic skills, Telegraph Science Correspondent Nick Collins explained on Saturday.

According to Collins, the researchers said the stimulation “should be offered within five weeks of a patient suffering a stroke because genes which allow the brain to recover are most active early on.”

He added the treatment is directed toward patients suffering from a condition known as aphasia – a disorder characterized by a disturbance of the comprehension and formulation of language caused by dysfunction in specific brain regions. Twenty to 30 percent of all stroke victims experience aphasia, Collins noted.

Lead author Alexander Thiel, an associate professor of neurology and neurosurgery at the university, and his colleagues recruited two dozen individuals who suffered from aphasia following an ischemic stroke (a stroke which occurs when blood flow to the brain is blocked by a clot or clogged artery), explained Linda Searing of the Washington Post.

Each of the 24 patients was randomly assigned to receive either transcranial magnetic stimulation (a procedure in which a magnetic coil is held over the patient’s head to stimulate nerve cells) or a false treatment which only stimulated the skin, Searing said. The treatments began five to seven days following the stroke, were administered each day for 20 minutes, and were followed up with 45 minutes of standard speech therapy.

“Standardized testing revealed that, after 10 days of treatment, improvement in speech and language skills was three times greater, on average, for people given the magnetic brain stimulation than for the others,” the Washington Post reporter said. “No one given the brain stimulation showed any decline in skills.”

“For decades, skilled speech and language therapy has been the only therapeutic option for stroke survivors with aphasia,” Thiel told the American Heart Association regarding his research. “We are entering exciting times where we might be able in the near future to combine speech and language therapy with non-invasive brain stimulation earlier in the recovery. This could result in earlier and more efficient aphasia recovery and also have an economic impact.”

http://www.redorbit.com/news/health/1112908682/stroke-speech-therapy-aided-by-magnetic-brain-stimulation-072913/

Thursday, July 11, 2013

Inhibitory Right-Brain TMS Improves Language After Stroke

 

Inhibitory Right-Brain TMS Improves Language After Stroke

Sue Hughes

Jul 11, 2013

Information from Industry

Use of inhibitory transcranial magnetic stimulation (TMS) over the speech area in the right side of the brain significantly improved language recovery in patients with stroke, new research shows.

"The dominant language center is normally in the left hemisphere of the brain. After a stroke, when this area is damaged, similar regions in the right hemisphere take over, but this is not as effective as if the left side recovers. Brain imaging studies show that stroke patients with right hemisphere activation generally do worse. So we used TMS treatment to inhibit the right hemisphere area, so the left hemisphere area has to function," lead investigator Alexander Thiel, MD, McGill University, Montreal, Quebec, Canada, told Medscape Medical News.

The study was published online June 27 in Stroke.

Editors' Recommendations

First Proof-of-Concept Study

Dr. Thiel compared the strategy with treating someone who has paralysis on 1 side of their body.

"If someone has paralysis of one arm, if you immobilize the good arm, the patient is forced to use the paralyzed arm, which helps it recover."

The inhibitory TMS is carried out by positioning a hand-held electromagnetic coil over the appropriate part of the brain. The fluctuating magnetic field induces an electrical current that blocks normal function.

Dr. Thiel noted that a few single case reports and case series of this treatment have been published previously, but this is the first randomized proof-of-concept study.

The study involved 24 patients (all right-handed) with subacute post-stroke aphasia from the rehabilitation hospital RehaNova in Cologne, Germany. They were randomly assigned to a 10-day protocol of 20-minute inhibitory 1-Hz TMS over the right triangular part of the posterior inferior frontal gyrus or sham stimulation, followed by 45 minutes of speech and language therapy.

Activity in language networks was measured with O-15-water positron emission tomography before and after treatment, and language performance was assessed by using the Aachen Aphasia Test (AAT) battery.

Results showed that language performance was significantly improved in the TMS group. The largest improvements were seen in the subtest of naming objects, but comprehension, token test, and writing also all improved.

Table. Change in Scores for Active TMS vs Sham

Variable
Difference in Scores Between Active and Sham Treatment
P Value

Global AAT score
16.2
.003

Comprehension
2.9
.082

Token test
2.9
.078

Naming
5.2
.002

Writing
3.1
.065

Repetition
2.0
Not significant

 

Imaging results showed that patients in the TMS group also activated proportionally more voxels in the left hemisphere language center after treatment than before (difference in activation volume index) compared with sham-treated patients. There was a moderate but significant linear relationship between activation volume index change and global AAT score change.

"We found that patients who underwent the real TMS treatment had 2-3 times better recovery of their aphasia than patients who were given the sham treatment. The principal improvement was in the ability to name objects. This is very important — you cannot communicate if you can't name things," said Dr. Thiel.

Pronounced Effect

"This study is telling us that this therapy seems to work the way we think it should. We are very excited by these results. We were a little surprised by the magnitude of the effect. We didn't expect it to be so pronounced. But the fact that the imaging results showed a shift in brain activity from the right to the left, corresponding with the improvement in aphasia, is reassuring and supports that this model is pathophysiologically valid."

He noted that the effect was measured immediately after the treatment. "How long it will last we don't know. Some previous studies suggest it does last long-term, but we need to study this further."

The next step is to try reproducing these results in a larger study. Such a study — NORTHSTAR — is now planned to start in October. Funded by the Canadian Institutes of Health Research, it will involve 100 patients from Canada and Germany. Patients will be assessed at day 10, as in the current study, but also longer term — about a month after treatment stops.

In the current study, patients were treated within 3 months after stroke. In the next study they will be treated within 1 month.

"We think the earlier we perform this treatment the more likely it is to be effective, as we believe there is a window of a few weeks after stroke when the right side of the brain becomes very active.

"We have seen this in imaging studies. Eventually it shifts back to the left. But the more the left brain takes over again the better the recovery. This treatment is just trying to accelerate this naturally occurring pattern," said Dr. Thiel.

Asked about risks, Dr. Thiel reported that aphasia did not deteriorate with the treatment.

When starting a patient with relapsing MS on treatment, what factors do you consider?

Learn more about this treatment option

Information from Industry

The main adverse effect is headaches because TMS can cause the scalp muscles to contract, but these are benign and respond to normal headache treatments, he said.

In rare cases TMS has been associated with seizures, but this did not occur in the current study.

"I would think seizures would be very unlikely as we are downregulating electrical activity and that should prevent seizures. TMS is inhibitory when used below 4 Hz and excitatory when used above 4 Hz. We used 1 Hz, so this will definitely be inhibitory," he said.

He noted that in theory it might be possible to use excitatory TMS on the damaged area of the left hemisphere, but this would be more difficult.

"As the infarct is there the primary language center is damaged and secondary language centers have taken over. We don't know exactly where these are, and the risks of inducing seizures would be greater from excitatory TMS."

The current study was funded by The Walter and Marga Boll and Wolf-Dieter-Heiss Foundations.

Stroke. Published online June 27, 2013. Abstract

http://www.medscape.com/viewarticle/807673

Monday, July 8, 2013

Stroke survivors may recover language function through brain stimulation

 
 

July 7, 2013

Stroke survivors may recover language function through brain stimulation
Non-invasive therapy delivered significant results

By James Limbach ConsumerAffairs.com The Press Republican Sun Jul 07, 2013, 06:00 AM EDT

Non-invasive brain stimulation may help stroke survivors recover speech and language function, according to new research in the American Heart Association journal Stroke.

Between 20 percent to 30 percent of stroke survivors have aphasia, a disorder that affects the ability to grasp language, read, write or speak. It's most often caused by strokes that occur in areas of the brain that control speech and language.

"For decades, skilled speech and language therapy has been the only therapeutic option for stroke survivors with aphasia," said Alexander Thiel, M.D., study lead author and associate professor of neurology and neurosurgery at McGill University in Montreal, Quebec, Canada. "We are entering exciting times where we might be able in the near future to combine speech and language therapy with non-invasive brain stimulation earlier in the recovery. This could result in earlier and more efficient aphasia recovery and also have an economic impact."
Aphasia treatment

In the small study, researchers treated 24 stroke survivors with several types of aphasia at the rehabilitation hospital Rehanova and the Max-Planck-Institute for neurological research in Cologne, Germany. Thirteen received transcranial magnetic stimulation (TMS) and 11 got sham stimulation.

The TMS device is a handheld magnetic coil that delivers low intensity stimulation and elicits muscle contractions when applied over the motor cortex.

During sham stimulation the coil is placed over the top of the head in the midline where there is a large venous blood vessel and not a language-related brain region. The intensity for stimulation was lower intensity so that participants still had the same sensation on the skin but no effective electrical currents were induced in the brain tissue.

Patients received 20 minutes of TMS or sham stimulation followed by 45 minutes of speech and language therapy for 10 days.
Significant results

The TMS groups' improvements were on average three times greater than the non-TMS group, researchers said. They used German language aphasia tests, which are similar to those in the United States, to measure language performance of the patients.

"TMS had the biggest impact on improvement in anomia, the inability to name objects, which is one of the most debilitating aphasia symptoms," Thiel said.

Researchers, in essence, shut down the working part of the brain so that the stroke-affected side could relearn language. "This is similar to physical rehabilitation where the unaffected limb is immobilized with a splint so that the patients must use the affected limb during the therapy session," Thiel said.

"We believe brain stimulation should be most effective early, within about five weeks after stroke, because genes controlling the recovery process are active during this time window," he said.

Story provided by ConsumerAffairs.

http://pressrepublican.com/fyi/x1333761866/Stroke-survivors-may-recover-language-function-through-brain-stimulation

Tuesday, October 30, 2012

Electric brain stimulation gains ground


Electric brain stimulation gains ground

NEUROLOGY Electric stimulation under study to treat brain trauma from stroke to Parkinson's and even dementia

Victoria Colliver

Published 5:15 p.m., Tuesday, October 30, 2012
 
Dr. Emily Kappenman (left) prepares psychologist Michael Callaghan for transcranial direct current stimulation. Photo: Sarah Rice, Special To The Chronicle / SF
Dr. Emily Kappenman (left) prepares psychologist Michael Callaghan for transcranial direct current stimulation. Photo: Sarah Rice, Special To The Chronicle / SF


Dr. Marom Bikson, who developed the transcranial direct current stimulation device, demonstrates the product at the Highland Hospital workshop. Photo: Sarah Rice, Special To The Chronicle / SF
Dr. Marom Bikson, who developed the transcranial direct current stimulation device, demonstrates the product at the Highland Hospital workshop. Photo: Sarah Rice, Special To The Chronicle / SF

 
Internist Kim Wood from Joplin, Mo., watches Marom Bikson demonstrate how to use the device. Photo: Sarah Rice, Special To The Chronicle / SF
Internist Kim Wood from Joplin, Mo., watches Marom Bikson demonstrate how to use the device. Photo: Sarah Rice, Special To The Chronicle / SF

Applying a current of electricity through the brain conjures up the kind of nightmare-inducing seizures immortalized in the 1975 film adaption of Ken Kesey's "One Flew Over the Cuckoo's Nest."
But a kinder, gentler, almost imperceptible form of electric brain stimulation - an experimental approach known as transcranial direct current stimulation - is gaining traction as a promising therapy for brain injuries due to stroke or other traumas, depression, dementia, attention-deficit disorder and other conditions.
Transcranial direct current stimulation, or tDCS, bears little in common with electroshock therapy or invasive forms of deep brain stimulation, which involve drilling holes in the head and implanting electrodes.
The level of the current used is tiny - typically between 1 and 2 milliamps, or less than one-one-hundredth of a single electrical watt. At most, the current causes a tingling or slight itching, if it's felt at all.
Even the technique's staunchest defenders acknowledge that the idea of treating a broad range of disorders with something you can hardly feel and that has few, if any, side effects sounds more like snake oil than science.
"How could this do anything? It seems so small. We're talking about a few volts," said Marom Bikson, associate professor of biomedical engineering at City University of New York who co-founded Soterix Medical Inc., a company that holds patents to Bikson's transcranial direct current stimulation devices.
Jolt to the brain
But Bikson said studies have shown a few volts of current can change the rate at which a brain cell fires in a way that is believed to improve brain plasticity, or its ability to change and learn new things.
"It's not some magical, unknown hocus-pocus," he said.
The concept is fairly simple: After dampened electrodes are strapped to a patient's scalp, a device charged by a 9-volt battery - the kind used in transistor radios - delivers a small current to change the activity in targeted regions of the brain.
The current, which is typically delivered for 10 to 30 minutes over multiple sessions, is thought to be able to excite or inhibit the brain's neurons in the stimulated area.
A positive current could help people with depression, stroke or other brain traumas, while a negative current may be helpful for such conditions as epilepsy or language recovery. Both currents can be used at the same time, and the effects of the stimulation are thought to continue or even increase, even after the device has been turned off.
Transcranial direct current stimulation has been used in a small number of hospitals - mostly on the East Coast - since about 2000 but has not been approved by the U.S. Food and Drug Administration. Soterix and other manufacturers plan to seek FDA approval for the devices once enough research has been done.
Earlier this month, Bikson was part of a research team that demonstrated the technique for doctors, therapists and other health experts during a one-day workshop at Alameda County Medical Center's Highland Hospital in Oakland.
Getting the word out
Dr. Lance Stone, medical director of rehabilitation and restoration at the county's Fairmont Hospital in San Leandro, was introduced to the technique earlier this year and invited the researchers to give his colleagues and other specialists the opportunity to learn more about it.
Stone is interested in the device's use in the emerging field of neurorehabilitation, which teaches or retrains patients with nervous system injuries such as stroke, Parkinson's disease or other brain trauma.
"There seems to be countless potential applications (of the technique) for acquired neurological disorders, but the main ones seem to be primarily pain, motor recovery and depression," said Stone, who plans to apply for a research grant to study the device.
The concept of using electrical stimulation for health purposes dates back thousands of years to the Greeks, whose medical practitioners were said to use electric eels in water to reduce symptoms of arthritis and other types of pain.
Modern usage of electroconvulsive therapy, formerly known as electroshock therapy, has been controversial, dating back to its early use in the 1940s and '50s in psychiatric hospitals. While it has been making a bit of a lower-voltage comeback in patients with severe depression, the method is generally considered a last resort because of the risk of memory loss and other side effects.
Trials and studies
Transcranial direct current stimulation has been around for decades, but the technique earned interest in the 1990s and early 2000s after some European physicians published promising results of the work. Currently it's the subject of numerous ongoing clinical trials and studies in this country.
In 2010, a team of Oxford University scientists published a small study that showed tDCS improved math skills in the majority of participants.
That same year, researchers at Beth Israel Deaconess Medical Center in Boston published findings that showed that the motor skills of stroke patients treated with the device, along with physical and occupational therapy, improved threefold compared with those who received a placebo form of stimulation and the same amount of physical and occupational therapy.
But some health experts warned that the technique's safety and effectiveness are unknown and that larger, controlled human clinical trials are needed.
"Whenever you do something - whether it's swallowing a drug or applying current - there may be a downside," said Dr. Sidney Wolfe, director of Public Citizen's Health Research Group, a consumer and health advocacy lobbying organization.
Sounds promising
Wolfe said the device sounds promising and is the subject of a myriad of clinical trials but shouldn't be approved until the larger, controlled studies are conducted. "The variety of medical problems for which they are trying this is enormous, and in most of the studies the number of patients is so small it's not statistically significant," he said.
Dr. Dylan Edwards, director of the Non-Invasive Brain Stimulation and Human Motor Control Laboratory at Burke Medical Research Institute in White Plains, N.Y., agreed that further research is needed to answer many of the unknown questions. His institute received a $3.5 million grant from the National Institutes of Health to study the device's effectiveness in stroke patients.
"The brain is an electrical organ," said Edwards. "What we're trying to do is develop methods that interfere with brain activity in a targeted way and positively influence it."
Edwards said several companies in the United States and around the world are already making transcranial direct current stimulation devices and he expects more.
Part of the appeal of the device is that it is relatively low cost - retailing for about $800. In addition, it's portable, so it can be used in many different settings.
Using on patients
Some doctors and researchers who attended the recent workshop had no experience using the device, while others had already tried it on a few patients. The device, which is considered investigational by the U.S. Food and Drug Administration, can be used either as part of a clinical trial or by a medical doctor for specific cases.
UC Berkeley psychologist Ludovica Labruna has experimented with using the device for language acquisition - to see if subjects could learn languages more quickly after receiving tDCS sessions. But she said her results have been somewhat disappointing, and she's not sure if she's using the device correctly.
"TDCS looks so simple, but it's really not so simple to apply because there are so many variables," Labruna said. "You really need to be trained."
Similar concerns drew Emily Kappenman to the workshop.
Kappenman, a postdoctoral researcher at UC Davis' Center for the Mind and Brain, said she's interested in the device's potential for working with patients with anxiety. She said she's tried it to see whether it helps people become less distracted and anxious by moving their attention away from certain emotions.
"It's hard to tell if it's working yet or if we're using optimal levels," she said. "It's hard to know what's best."
Brain stimulation
Brain stimulation uses magnetic or electrical energy to improve brain function. Here are some of the techniques in use or being studied:
Electroconvulsive therapy (ECT): With ECT, an electric current passes briefly through the scalp to the brain, inducing a seizure. It's generally considered only for those with severe depression or other serious mental illnesses who do not respond to other treatments.
Transcranial magnetic stimulation (TMS): TMS uses wrapped coil wires to generate electric current throughout the scalp and can induce involuntary movements. Although it has a few potentially serious side effects, including seizures, the treatment received federal approval for patients with severe depression in 2008.
Transcranial direct current stimulation (tDCS): Weaker still than TMS, tDCS has not been approved, but researchers are studying its use to help patients with strokes and other brain injuries. It has also been considered for use in healthy subjects, with researchers testing everything from memory enhancement to improved golf swing.
Source: Chronicle research
Victoria Colliver is a San Francisco Chronicle staff writer. E-mail: vcolliver@sfchronicle.com